Who invested in Tubulis

One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$401Mraised across 1 round since 2025, from 1 source

Latest round: Series C, $401MOct 2025
Investors: 5

See who backed them

The rounds

Oct 2025
Series C$401M
Source recorded

Founders and team

From Tubulis's own website: 56 on the team.

Andreas MontagVice President Finance
Dr. Annette VoglVice President Biology and Translational Research
Dr. Armin WeidmannSenior Vice President Quality
Dr. Marc-André KasperVice President Chemistry and Early Development
Dr. Moetaz B. AlbizemSenior Vice President and Head of Clincal Operations
Dr. Olivier MarcqSenior Vice President CMC
Dr. Yariv HouvrasVice President Clinical and Translational Development
Mary Ann LumiquedVice President Program Management
Ramola BhandarkarSenior Vice President Regulatory Affairs
Bettina DeisenriederExecutive Assistant to the CEO
Dr. Dominik SchumacherCEO
Adriane KraheGlobal Head of HR
Dr. Bernhard SeehausGlobal Head of Intellectual Property
Eckart FreheHead of IT
Anastasia KazanisSenior Operations Manager
Andrea MathieuFinancial Operations Specialist
Arijana PopadicOffice Manager
Christina BauerHR Manager

And 38 more on the team.

Everyone who backed them

Wellington ManagementVC firm1round

Seventure PartnersVC firm1round

Janus Henderson InvestorsPrivate equity1round

EQT Life SciencesVC firm1round

Andera PartnersPrivate equity1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 3 firms list Tubulis as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.